0001213900-18-012588.txt : 20180914 0001213900-18-012588.hdr.sgml : 20180914 20180914172322 ACCESSION NUMBER: 0001213900-18-012588 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180914 DATE AS OF CHANGE: 20180914 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Propanc Biopharma, Inc. CENTRAL INDEX KEY: 0001517681 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300662986 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-87562 FILM NUMBER: 181071910 BUSINESS ADDRESS: STREET 1: 302/6 BUTLER STREET CITY: CAMBERWELL, VICTORIA STATE: C3 ZIP: 3124 BUSINESS PHONE: 613-9882-6723 MAIL ADDRESS: STREET 1: 302/6 BUTLER STREET CITY: CAMBERWELL, VICTORIA STATE: C3 ZIP: 3124 FORMER COMPANY: FORMER CONFORMED NAME: Propanc Health Group Corp DATE OF NAME CHANGE: 20110408 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Coventry Enterprises,LLC CENTRAL INDEX KEY: 0001539756 IRS NUMBER: 000000000 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 80 SW 8TH STREET STREET 2: SUITE 2000 CITY: MIAMI STATE: FL ZIP: 33130 BUSINESS PHONE: 212-363-2900 MAIL ADDRESS: STREET 1: 80 SW 8TH STREET STREET 2: SUITE 2000 CITY: MIAMI STATE: FL ZIP: 33130 SC 13G 1 sc13g0918coventry_propanc.htm SCHEDULE 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. __)

 

Propanc Biopharma, Inc.

 

(Name of Issuer)

 

Common stock

(Title of Class of Securities)

 

74346N107

 

(CUSIP Number)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐    Rule 13d-1(b)

☒    Rule 13d-1(c)

☐    Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

1.

NAMES OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

Coventry Enterprises, LLC EIN# 27-335-1562

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

(a) ☐

(b) ☐

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

5.

SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON –

 

12,500,000

6.

SHARED VOTING POWER - 

 

7.

SOLE DISPOSITIVE POWER –

 

12,500,000

8.

SHARED DISPOSITIVE POWER - 

 

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -

 

12,500,000

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

9.61%

12.

TYPE OF REPORTING PERSON

 

PN

 

 1 

 

 

ITEM 1 (a) NAME OF ISSUER: Propanc Biopharma, Inc.

 

ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 302, 6 Butler Street Camberwell, VC 3124 Australia

 

ITEM 2 (a) NAME OF PERSON FILING: Coventry Enterprises, LLC

 

ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: 80 SW 8th street Suite 2000 Miami FL 33130

 

ITEM 2 (c) CITIZENSHIP: USA

 

ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common

 

ITEM 2 (e) CUSIP NUMBER: 74346N107

 

ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

 

(a)  ☐ Broker or dealer registered under Section 15 of the Exchange Act.
(b)  ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)  ☐ Insurance Company defined in Section 3(a)(19) of the Exchange Act.
(d)  ☐ Investment Company registered under Section 8 of the Investment Company Act.
(e)  ☐ An Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E)
(f)  ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(ii)(F)
(g)  ☐ A parent holding company or control person in accordance Rule 13d-1(b)(1)(ii)(G)
(h)  ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)  ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j)  ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(J)

  

ITEM 4 OWNERSHIP

 

(a) AMOUNT BENEFICIALLY OWNED: 12,500,000

 

(b) PERCENT OF CLASS: 9.61%

 

(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

 

(i)   SOLE POWER TO VOTE OR DIRECT THE VOTE 12,500,000

 

(ii)  SHARED POWER TO VOTE OR DIRECT THE VOTE

 

(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF 12,500,000

 

(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

 

ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

  

ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

 

ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

 

ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

 

ITEM 9   NOTICE OF DISSOLUTION OF GROUP

 

ITEM 10. CERTIFICATION.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect

 

 2 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

   September 6, 2018
   (Date)
   
   /s/ Jack Bodenstien

 

 

3